or Try an Advanced Search...

    Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 10.99 -6.67% -0.79
    ZNTL closed down 6.36 percent on Wednesday, April 24, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 8
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ZNTL trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion -6.67%
    Oversold Stochastic Weakness -6.67%
    Outside Day Range Expansion -12.61%
    Wide Bands Range Expansion -12.61%
    Oversold Stochastic Weakness -12.61%
    Wide Bands Range Expansion -15.50%
    Oversold Stochastic Weakness -15.50%
    Bullish Engulfing Bullish -15.24%
    Stochastic Buy Signal Bullish -15.24%
    Pocket Pivot Bullish Swing Setup -15.24%
    Older End-of-Day Signals for ZNTL ...

       Recent Intraday Alerts

    Alert Time
    Down 10% about 5 hours ago
    60 Minute Opening Range Breakdown about 6 hours ago
    Down 1 ATR about 6 hours ago
    Gapped Down (Full) about 7 hours ago
    Down 5% about 7 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ZNTL Chart by TradingView
    Basic chart:

    Profile

    Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Estrogen Molecule Therapeutics Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors Metastatic Breast Cancer

    Is ZNTL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 12 Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
    Apr 11 Zentalis Pharmaceuticals says Melissa Epperly resigns as CFO
    Apr 2 Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
    Mar 1 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Feb 29 Zentalis files automatic mixed securities shelf
    Feb 29 Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Price
    Feb 28 Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet
    Feb 28 Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
    Feb 28 Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...
    Feb 27 Zentalis Pharmaceuticals GAAP EPS of -$4.47 beats by $0.06
    See more ZNTL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 31.46
    52 Week Low 9.56
    Average Volume 833,981
    200-Day Moving Average 17.34
    50-Day Moving Average 14.03
    20-Day Moving Average 14.06
    10-Day Moving Average 12.85
    Average True Range 0.94
    RSI (14) 35.48
    ADX 17.73
    +DI 13.67
    -DI 26.78
    Chandelier Exit (Long, 3 ATRs) 13.42
    Chandelier Exit (Short, 3 ATRs) 14.46
    Upper Bollinger Bands 16.67
    Lower Bollinger Band 11.45
    Percent B (%b) 0.06
    BandWidth 37.12
    MACD Line -0.53
    MACD Signal Line -0.28
    MACD Histogram -0.2514
    Fundamentals Value
    Market Cap 832.91 Million
    Num Shares 70.8 Million
    EPS -4.56
    Price-to-Earnings (P/E) Ratio -2.58
    Price-to-Sales 0.00
    Price-to-Book 1.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.21
    Resistance 3 (R3) 13.32 12.96 12.97
    Resistance 2 (R2) 12.96 12.59 12.90 12.89
    Resistance 1 (R1) 12.36 12.36 12.18 12.25 12.81
    Pivot Point 12.00 12.00 11.91 11.94 12.00
    Support 1 (S1) 11.40 11.63 11.22 11.29 10.73
    Support 2 (S2) 11.04 11.40 10.98 10.65
    Support 3 (S3) 10.44 11.04 10.57
    Support 4 (S4) 10.33